Lifecare ASA: Mandatory notification of trade

29 Jan 2026 17:04 CET

Reference is made to announcements made by Lifecare ASA (the "Company") on 23
January 2026 and 29 January 2026 regarding the allocation of in total 940,261
shares and 1,410,392 warrants to Hans Hekland, board member of the Company, in
a rights issue and as settlement of his entitlement to underwriting commission
as an underwriter of the rights issue. The Company has been informed that all
such shares and warrants that were allocated to Hans Hekland have been agreed
transferred to Hannibal Invest AS, a company closely associated with Hans
Hekland.

The transfer does not affect the total number of issued shares or warrants in
the Company.

Please see the attached PDMR form for further details.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-01-29 17:04 CET.

More information:
Access the news on Oslo Bors NewsWeb site

664475_PDMR Attachment Hannibal Invest AS.pdf
664475_Lifecare ASA- Mandatory notification of trade.pdf